Hoth Therapeutics and UCRI sign research agreement to perform critical studies to streamline development of HT-006. Credit: Bearcat2011 / Wikipedia.

Hoth Therapeutics and the University of Cincinnati Research Institute (UCRI) in the US have signed a research agreement to conduct critical antimicrobial characterisation studies for the streamlined development of the antibiotic HT-006.

HT-006 is a new molecular entity (NME) developed by the Walter Reed Army Institute of Research (WRAIR) using a novel antibacterial action mechanism that targets multiple bacterial pathogens.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is currently under development as a potential treatment for multi-drug resistant bacterial infections of lung-like hospital-acquired pneumonia (HAP), cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and ventilator-associated pneumonia (VAP).

The company earlier licensed the technology from the WRAIR for commercial evaluation.

The new research programme is led by the University of Cincinnati (UC) College of Medicine, Department of Molecular Genetics, Biochemistry and Microbiology professor Daniel Hassett.

Hoth Therapeutics CEO Robb Knie said: “We are pleased to commence a new research programme with Dr Hassett and the University of Cincinnati Research Institute (UCRI).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“There is a growing need for new antibiotic therapies targeted at multi-drug resistant bacteria, particularly for life-threatening conditions like hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).

“The work to be conducted by Dr Hassett will assist in expediting the HT-006 drug development programme towards the clinic.”

The research will focus on studying pathogenic mechanisms of multi-drug resistant bacteria and effective antimicrobial strategies to fight these organisms.

This plan includes critical antimicrobial in vitro characterisation studies for the novel antibiotic HT-006 in alignment with the US Food and Drug Administration (FDA) programme for antibacterial therapies.

Hoth Therapeutics stated that, through this streamlined programme, nonclinical animal studies will be used to reduce clinical studies required for approval.